February 1, 2008 - Abbott has received reimbursement approval in France for its XIENCE V Everolimus Eluting Coronary ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
February 1, 2008 - Medtronic Inc. has received approval from the FDA for the Endeavor Zotarolimus-Eluting Coronary Stent ...
January 31, 2008
January 24, 2008 – “Unadjusted mortality…was significantly lower for drug-eluting stents than bare-metal stents ...
January 23, 2008January 22, 2008 - A new stent with a nanothin surface application known as Polyzene-F shows promise in opening ...
January 21, 2008January 14, 2008 - Drug-eluting stents in patients undergoing coronary artery revascularization procedures relieve ...
January 13, 2008January 10, 2008 - Patients who received OrbusNeich’s Genous Bio-engineered R Stent had significantly fewer major ...
January 09, 2008January 8, 2008 - Compared with paclitaxel-eluting stents (PES), sirolimus-eluting stents (SES) appear to decrease ...
January 07, 2008December 27, 2007 - XTENT Inc. announced that it has submitted its application to the designated European Notified Body ...
December 26, 2007December 27, 2007 - Several new studies on genetics and stem cell research, along with studies that continue to ...
December 26, 2007December 26, 2007 - Boston Scientific Corp. announced its TAXUS Liberte paclitaxel-eluting coronary stent system has ...
December 26, 2007December 17, 2007 - Patients treated with drug-eluting stents must take a combination of aspirin and the clot-reducing ...
December 16, 2007December 14, 2007 - According to a guideline update published online today in the journals of the Society for ...
December 13, 2007December 13, 2007 - Devax Inc. announced that it has completed patient enrollment in the DIVERGE clinical trial ...
December 12, 2007December 6, 2007 — The Circulatory System Devices Advisory Panel to the FDA has recommended approval for the XIENCE V ...
December 05, 2007December 6, 2007 - Boston Scientific Corp. welcomed the recommendation of a FDA advisory panel to approve with ...
December 05, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now